|
 Many of the pharmaceutical products that reach the market today offer only modest benefits over existing therapies. At Savient, our approach to clinical development has been much more inspired. We have primarily targeted compounds with the potential to provide relief to patients with serious conditions.
Our current development program is focused on a new treatment option that will serve niche markets worldwide. We believe our late stage biologic product pegloticase (KRYSTEXXA™) has potential for addressing important gaps in the care and management of patients with chronic gout refractory to conventional therapy.
|
